Silica for 3D Printing: Uses in Resins, Powders and Binder Jetting

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica Sol Manufacturer: Product Types, Quality Control and How to Choose
  • Keywords: does silicon dioxide conduct electricity
  • Published: 2026-11-20 12:17:06
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
With the continuous research and growth of nanotechnology in the biomedical fields, the global healthcare nanotechnology market is expected to grow gradually from US$ 17,245 million in 2019 to US$ 252,400 million by 2024. 505 As an essential part of the nanomaterials library, MSNs have become indispensable in the biomedical field owing to their easily tunable structure and composition, relatively excellent biocompatibility, and versatile surface functionalization properties. Their footprints have covered diverse aspects, serving as carriers to deliver diverse therapeutic agents, as matrixes to construct nanocomposites for meeting particular requirements, or as productive agents with intrinsic therapeutic influence or bioactivity.

What Is Fused Silica Sand? Properties and Uses in Investment Casting and Refractories

Silica Aerogel Powder: Properties, Applications and How It Compares to Other Insulators
Custom Silica: Tailoring Particle Size, Surface Treatment and Purity to Your Application
Geng, S. et al. Effective and secure delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo. Biomaterials 271, 120763 (2021). Article CAS PubMed Google Scholar
Fumed Silica Brands Compared: Aerosil, Cab-O-Sil, HDK and Chinese Alternatives
Azharuddin, M. et al. A repertoire of biomedical applications of noble metal nanoparticles. Chem. Commun. 55, 6964-6996 (2019). Article CAS Google Scholar
Silica Production Process: Step-by-Step Guide for Fumed, Precipitated and Fused Silica

Spherical Silica Market 2026: Semiconductor Packaging Demand and Growth Outlook

What is silica (SiO₂)?

silica gel manufacturer

What is the difference between fumed silica and precipitated silica?

fumed silica 200 m2/g Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.

What drives silica raw material prices?

HDK N20

Cite this article: Silica Raw Materials News. "Is There a Quartz Sand Shortage? Causes, Impact and Supply Outlook ." Published 2026-11-20 12:17:06. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.